RCKT - rocketpharma.com Earnings growth forecast for next year
Rocket Pharmaceuticals (RCKT) relies on an independent product cycle, which renders the asset a defensive tool. The valuation of future earnings per share growth confirms this trend, with the latest mark standing at -896.60. Development efficiency is increasing due to robotic bioscreening; however, potential FDA delays and the high cost of gene therapy production threaten financial stability.
Analytical breakdowns for Rocket Pharmaceuticals
- price and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- company total debt and liquidity indicators:
Debt to Equity Rocket Pharmaceuticals|RCKT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Rocket Pharmaceuticals, Inc.|RCKT - Company Aggregate Debts|Debts to Book Capitalization Rocket Pharmaceuticals|RCKT - Company Long-Term Liabilities|Company Short-Term Debts Rocket Pharmaceuticals|Quick Liquidity Indicator rocketpharma.com
- earnings and valuation multiples information:
RCKT - Net Profit|Future Profit Rocket Pharmaceuticals|RCKT - Market Price to Net Income Ratio|Forward P/E Multiple Rocket Pharmaceuticals|RCKT - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Rocket Pharmaceuticals|RCKT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Rocket Pharmaceuticals|RCKT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months rocketpharma.com|RCKT - Earnings per share growth in current year|Net earnings per share growth forecast for next year Rocket Pharmaceuticals
- revenue and sales proceeds data:
Basic company analysis:Rocket Pharmaceuticals Inc, RCKT
Rocket Pharmaceuticals focuses on the commercialization of gene therapies for orphan diseases, where success depends on manufacturing scalability. The historical trend of the next year's EPS forecast reflects the daily adjustment of analyst expectations for net income. Growth in this indicator confirms a fundamental strengthening of the business, while a plateau suggests that market equilibrium has been reached. For the investor, an upward breakout from the range signals that Rocket Pharmaceuticals is transitioning to a stage of sustainable profitability.
Analysis of competing companies
Net earnings per share growth forecast for next year Tempus AI, Inc|Qiagen Corp - Net earnings per share change forecast for next year|Earnings growth forecast for next year IONS|RGEN (repligen.com) - Expected earnings per share trend next year|Earnings growth forecast for next year RNA (Avidity Biosciences, Inc.)|Earnings growth forecast for next year CRISPR Therapeutics Inc CRSP|WGS - Net earnings per share growth forecast for next year|Expected earnings per share trend next year RARE (Ultragenyx Corp)|Beam Therapeutics Inc. (BEAM) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year sarepta.com|TWST (Twist Bioscience, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year 10x Genomics Inc|Earnings growth forecast for next year NTLA|Expected earnings per share growth for next year Stoke Corp STOK|Earnings growth forecast for next year BLFS (BioLife Solutions, Inc.)|wavelifesciences.com (WVE) - Expected net earnings per share growth next year|MAZE: Expected earnings per share growth for next year|SION - Earnings growth forecast for next year|PRME (Prime Medicine Corp) - Expected earnings per share growth for next year|TSHA: Projected earnings per share increase next year|QURE (uniQure N.V.) - Earnings growth forecast for next year|meiragtx.com (MGTX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year RGNX|Expected earnings per share growth for next year Solid Biosciences Inc SLDB|Earnings growth forecast for next year OCGN (Ocugen Corp)|Earnings growth forecast for next year PacBio Corp PACB|BNTC - Net earnings per share growth forecast for next year|DSGN: Net earnings per share growth forecast for next year|4D Molecular Therapeutics, Inc. (FDMT) - Net earnings per share growth forecast for next year|LXEO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Korro Bio Inc.|EDIT: Expected earnings per share trend next year|Earnings growth forecast for next year SLN|Expected earnings per share growth for next year proqr.com PRQR|Net earnings per share growth forecast for next year Codexis CDXS|Earnings growth forecast for next year Sangamo Therapeutics Inc. SGMO|NAUT: Expected earnings per share growth for next year|Metagenomi Therapeutics - Projected earnings per share increase next year|DTIL: Earnings growth forecast for next year|Projected earnings per share growth rate for next year GBIO|Net earnings per share growth forecast for next year Boundless Bio|Projected earnings per share growth rate for next year XCUR (Exicure Corp)|Earnings growth forecast for next year IMNN|Earnings growth forecast for next year phiopharma.com (PHIO)|Net earnings per share growth forecast for next year Mustang Bio MBIO|Expected earnings per share trend next year RNAZ|BNGO - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Applied DNA Sciences Inc|BLUE: Earnings growth forecast for next year|Expected earnings per share growth for next year ImmunoPrecise Antibodies Ltd.|Net earnings per share growth forecast for next year Omega Therapeutics|Earnings growth forecast for next year singulargenomics.com|Earnings growth forecast for next year RGLS|SYRS - Expected net earnings per share growth next year|Codex DNA - Expected earnings per share growth for next year|Projected earnings per share increase next year TCON (TRACON Pharmaceuticals, Inc)|UBX: Expected earnings per share growth for next year
